- Home
- ENGN vs FDMT Comparison
ENGN vs FDMT Comparison
Compare ENGN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- FDMT
- Stock Information
- Founded
- ENGN 1999
- FDMT 2013
- Country
- ENGN Canada
- FDMT United States
- Employees
- ENGN N/A
- FDMT N/A
- Industry
- ENGN
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- FDMT Health Care
- Exchange
- ENGN Nasdaq
- FDMT Nasdaq
- Market Cap
- ENGN 191.1M
- FDMT 192.2M
- IPO Year
- ENGN N/A
- FDMT 2020
- Fundamental
- Price
- ENGN $3.37
- FDMT $4.32
- Analyst Decision
- ENGN Buy
- FDMT Buy
- Analyst Count
- ENGN 7
- FDMT 10
- Target Price
- ENGN $23.29
- FDMT $32.33
- AVG Volume (30 Days)
- ENGN 83.9K
- FDMT 436.5K
- Earning Date
- ENGN 09-09-2025
- FDMT 08-07-2025
- Dividend Yield
- ENGN N/A
- FDMT N/A
- EPS Growth
- ENGN N/A
- FDMT N/A
- EPS
- ENGN N/A
- FDMT N/A
- Revenue
- ENGN N/A
- FDMT $23,000.00
- Revenue This Year
- ENGN N/A
- FDMT $13,048.65
- Revenue Next Year
- ENGN N/A
- FDMT N/A
- P/E Ratio
- ENGN N/A
- FDMT N/A
- Revenue Growth
- ENGN N/A
- FDMT N/A
- 52 Week Low
- ENGN $2.65
- FDMT $2.24
- 52 Week High
- ENGN $11.00
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- ENGN 40.69
- FDMT 57.43
- Support Level
- ENGN $2.95
- FDMT $3.86
- Resistance Level
- ENGN $3.98
- FDMT $4.48
- Average True Range (ATR)
- ENGN 0.27
- FDMT 0.28
- MACD
- ENGN 0.02
- FDMT 0.01
- Stochastic Oscillator
- ENGN 34.29
- FDMT 89.81
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.